Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lupus Erythematosus, Systemic | 43 | 2022 | 756 | 6.750 |
Why?
|
Lupus Nephritis | 19 | 2022 | 193 | 5.670 |
Why?
|
Neutrophils | 3 | 2020 | 204 | 1.730 |
Why?
|
Nitric Oxide | 11 | 2017 | 382 | 1.680 |
Why?
|
Endothelium, Vascular | 4 | 2022 | 371 | 1.530 |
Why?
|
Nitric Oxide Synthase Type III | 5 | 2015 | 102 | 1.490 |
Why?
|
Sphingolipids | 4 | 2021 | 337 | 1.360 |
Why?
|
Nitric Oxide Synthase Type II | 8 | 2015 | 201 | 1.260 |
Why?
|
Kidney | 7 | 2021 | 945 | 1.250 |
Why?
|
Interferon-alpha | 3 | 2017 | 46 | 1.200 |
Why?
|
Nitric Oxide Synthase | 7 | 2017 | 163 | 1.160 |
Why?
|
Proteinuria | 8 | 2021 | 136 | 1.150 |
Why?
|
Reactive Oxygen Species | 4 | 2013 | 499 | 1.150 |
Why?
|
Mentoring | 6 | 2019 | 53 | 1.090 |
Why?
|
Reactive Nitrogen Species | 4 | 2010 | 32 | 0.950 |
Why?
|
Biomarkers | 13 | 2021 | 1593 | 0.950 |
Why?
|
Self Care | 2 | 2017 | 252 | 0.940 |
Why?
|
Endothelial Cells | 4 | 2022 | 384 | 0.870 |
Why?
|
Autoimmune Diseases | 4 | 2020 | 186 | 0.830 |
Why?
|
Tool Use Behavior | 1 | 2021 | 4 | 0.800 |
Why?
|
Female | 55 | 2022 | 38021 | 0.760 |
Why?
|
Carotid Artery Diseases | 1 | 2021 | 83 | 0.750 |
Why?
|
Neurosciences | 1 | 2020 | 15 | 0.740 |
Why?
|
Kidney Glomerulus | 4 | 2020 | 155 | 0.710 |
Why?
|
Humans | 71 | 2022 | 68549 | 0.700 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 161 | 0.690 |
Why?
|
Mice, Inbred MRL lpr | 11 | 2022 | 118 | 0.630 |
Why?
|
Enzyme Inhibitors | 7 | 2013 | 659 | 0.620 |
Why?
|
Vascular Diseases | 2 | 2015 | 94 | 0.600 |
Why?
|
Inflammation | 6 | 2022 | 1030 | 0.600 |
Why?
|
Adult | 35 | 2022 | 21379 | 0.590 |
Why?
|
Autoantibodies | 9 | 2022 | 434 | 0.580 |
Why?
|
Blood Vessels | 1 | 2017 | 102 | 0.580 |
Why?
|
Electronic Health Records | 5 | 2022 | 374 | 0.570 |
Why?
|
Chemokine CCL2 | 2 | 2015 | 101 | 0.550 |
Why?
|
Health Status Disparities | 1 | 2019 | 326 | 0.540 |
Why?
|
Extracellular Traps | 1 | 2015 | 9 | 0.540 |
Why?
|
Nitrites | 5 | 2011 | 53 | 0.520 |
Why?
|
Nitrates | 5 | 2011 | 61 | 0.520 |
Why?
|
Endothelium | 1 | 2015 | 98 | 0.520 |
Why?
|
Biomedical Research | 3 | 2017 | 310 | 0.520 |
Why?
|
Self-Management | 5 | 2019 | 82 | 0.520 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2015 | 23 | 0.510 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 2015 | 20 | 0.510 |
Why?
|
Superoxides | 2 | 2013 | 70 | 0.500 |
Why?
|
Social Support | 2 | 2018 | 423 | 0.500 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 71 | 0.500 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 170 | 0.490 |
Why?
|
Tyrosine | 4 | 2013 | 196 | 0.490 |
Why?
|
Cholecalciferol | 1 | 2015 | 143 | 0.490 |
Why?
|
Atherosclerosis | 2 | 2015 | 204 | 0.470 |
Why?
|
Neuropeptides | 1 | 2015 | 106 | 0.470 |
Why?
|
Male | 33 | 2022 | 37283 | 0.470 |
Why?
|
Mice | 19 | 2022 | 8474 | 0.470 |
Why?
|
Kidney Cortex | 1 | 2013 | 19 | 0.460 |
Why?
|
Podocytes | 1 | 2015 | 113 | 0.460 |
Why?
|
Vitamin D Deficiency | 2 | 2015 | 292 | 0.450 |
Why?
|
NADPH Oxidases | 1 | 2013 | 80 | 0.440 |
Why?
|
Adamantane | 1 | 2013 | 40 | 0.430 |
Why?
|
Apoptosis | 5 | 2015 | 1641 | 0.430 |
Why?
|
Animals | 24 | 2022 | 20880 | 0.420 |
Why?
|
Scleroderma, Systemic | 6 | 2021 | 446 | 0.420 |
Why?
|
Hypertension | 1 | 2022 | 1533 | 0.420 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 938 | 0.410 |
Why?
|
Models, Biological | 1 | 2016 | 981 | 0.410 |
Why?
|
Vitamin D | 2 | 2015 | 516 | 0.410 |
Why?
|
Antibodies, Antinuclear | 6 | 2022 | 171 | 0.400 |
Why?
|
Sulfonamides | 2 | 2011 | 141 | 0.400 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 201 | 0.390 |
Why?
|
Lipopolysaccharides | 6 | 2019 | 455 | 0.390 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 282 | 0.390 |
Why?
|
Quality of Life | 5 | 2019 | 1515 | 0.390 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2011 | 46 | 0.390 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2013 | 200 | 0.390 |
Why?
|
Lysine | 2 | 2008 | 96 | 0.380 |
Why?
|
Thromboxane A2 | 1 | 2011 | 88 | 0.380 |
Why?
|
Complement System Proteins | 2 | 2013 | 135 | 0.380 |
Why?
|
Pyridines | 1 | 2013 | 261 | 0.380 |
Why?
|
Middle Aged | 26 | 2022 | 21119 | 0.380 |
Why?
|
Pyrazoles | 2 | 2011 | 190 | 0.360 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2022 | 45 | 0.350 |
Why?
|
Microbiota | 2 | 2022 | 79 | 0.350 |
Why?
|
Leukocytes, Mononuclear | 2 | 2022 | 124 | 0.340 |
Why?
|
Cell Proliferation | 1 | 2013 | 1174 | 0.330 |
Why?
|
Disease Models, Animal | 9 | 2021 | 2550 | 0.330 |
Why?
|
Young Adult | 13 | 2022 | 5710 | 0.330 |
Why?
|
Predictive Value of Tests | 5 | 2021 | 1465 | 0.320 |
Why?
|
Spleen | 2 | 2013 | 301 | 0.320 |
Why?
|
Prospective Studies | 4 | 2021 | 3703 | 0.320 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 2 | 2021 | 106 | 0.300 |
Why?
|
Fibroblasts | 4 | 2021 | 902 | 0.300 |
Why?
|
Cytokines | 3 | 2022 | 866 | 0.290 |
Why?
|
Up-Regulation | 3 | 2022 | 682 | 0.280 |
Why?
|
Early Diagnosis | 1 | 2007 | 122 | 0.280 |
Why?
|
Autoantigens | 2 | 2017 | 91 | 0.270 |
Why?
|
Oxidative Stress | 3 | 2010 | 718 | 0.270 |
Why?
|
Gene Expression Regulation | 4 | 2019 | 1293 | 0.270 |
Why?
|
History, 20th Century | 2 | 2020 | 248 | 0.260 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 3 | 2002 | 66 | 0.260 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 514 | 0.250 |
Why?
|
Antibodies, Monoclonal | 3 | 2015 | 511 | 0.250 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 2265 | 0.240 |
Why?
|
Health Behavior | 2 | 2019 | 458 | 0.240 |
Why?
|
Biopsy | 3 | 2013 | 539 | 0.230 |
Why?
|
Lymphocytes | 1 | 2004 | 228 | 0.220 |
Why?
|
Gastrointestinal Microbiome | 2 | 2022 | 121 | 0.220 |
Why?
|
Severity of Illness Index | 6 | 2018 | 1851 | 0.220 |
Why?
|
Clinical Trials as Topic | 3 | 2014 | 848 | 0.210 |
Why?
|
Case-Control Studies | 4 | 2019 | 1549 | 0.210 |
Why?
|
Genetic Diseases, X-Linked | 1 | 2022 | 24 | 0.210 |
Why?
|
Pilot Projects | 6 | 2019 | 1341 | 0.210 |
Why?
|
Polymyalgia Rheumatica | 1 | 2022 | 5 | 0.210 |
Why?
|
Genetic Predisposition to Disease | 4 | 2022 | 786 | 0.200 |
Why?
|
Giant Cell Arteritis | 1 | 2022 | 10 | 0.200 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2022 | 52 | 0.200 |
Why?
|
Sjogren's Syndrome | 1 | 2022 | 18 | 0.200 |
Why?
|
B-Lymphocyte Subsets | 1 | 2022 | 25 | 0.200 |
Why?
|
Thromboxane B2 | 2 | 2013 | 108 | 0.200 |
Why?
|
MicroRNAs | 3 | 2022 | 447 | 0.200 |
Why?
|
E2F Transcription Factors | 1 | 2022 | 48 | 0.200 |
Why?
|
Patient Participation | 3 | 2019 | 145 | 0.200 |
Why?
|
Topoisomerase Inhibitors | 1 | 2021 | 4 | 0.200 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 43 | 0.200 |
Why?
|
Topotecan | 1 | 2021 | 17 | 0.200 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 301 | 0.200 |
Why?
|
Caveolin 1 | 2 | 2013 | 59 | 0.200 |
Why?
|
Peer Group | 2 | 2019 | 104 | 0.200 |
Why?
|
Camptothecin | 1 | 2021 | 39 | 0.200 |
Why?
|
Interleukin-10 | 1 | 2022 | 144 | 0.190 |
Why?
|
Staphylococcus aureus | 1 | 2022 | 175 | 0.190 |
Why?
|
Transcription Factors | 3 | 2002 | 753 | 0.190 |
Why?
|
Laboratories | 1 | 2021 | 44 | 0.190 |
Why?
|
DNA | 4 | 2022 | 597 | 0.190 |
Why?
|
Glucuronidase | 1 | 2020 | 11 | 0.190 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2021 | 151 | 0.190 |
Why?
|
Prognosis | 2 | 2021 | 2093 | 0.190 |
Why?
|
Photography | 1 | 2020 | 37 | 0.190 |
Why?
|
Rheumatic Diseases | 1 | 2020 | 35 | 0.180 |
Why?
|
Plaque, Atherosclerotic | 1 | 2021 | 125 | 0.180 |
Why?
|
Spouses | 1 | 2020 | 51 | 0.180 |
Why?
|
History, 21st Century | 1 | 2020 | 126 | 0.180 |
Why?
|
Anti-Inflammatory Agents | 1 | 2002 | 234 | 0.180 |
Why?
|
Peer Influence | 1 | 2019 | 7 | 0.170 |
Why?
|
Serologic Tests | 2 | 2018 | 46 | 0.170 |
Why?
|
Occludin | 1 | 2019 | 7 | 0.170 |
Why?
|
Bacterial Translocation | 1 | 2019 | 27 | 0.170 |
Why?
|
Time Factors | 4 | 2021 | 4655 | 0.170 |
Why?
|
DNA Methylation | 1 | 2021 | 193 | 0.170 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 163 | 0.170 |
Why?
|
Enzyme Induction | 2 | 2015 | 118 | 0.170 |
Why?
|
Ultrasonography | 1 | 2021 | 453 | 0.170 |
Why?
|
omega-N-Methylarginine | 3 | 2005 | 14 | 0.160 |
Why?
|
Mass Spectrometry | 1 | 2019 | 284 | 0.160 |
Why?
|
Mice, Knockout | 3 | 2013 | 1692 | 0.160 |
Why?
|
Algorithms | 4 | 2022 | 1195 | 0.160 |
Why?
|
Thrombosis | 2 | 2015 | 218 | 0.160 |
Why?
|
Mice, Inbred BALB C | 4 | 2011 | 532 | 0.160 |
Why?
|
Immunologic Factors | 2 | 2010 | 87 | 0.160 |
Why?
|
Progesterone | 1 | 2019 | 115 | 0.160 |
Why?
|
Blood Proteins | 2 | 2013 | 94 | 0.150 |
Why?
|
Feasibility Studies | 2 | 2018 | 652 | 0.150 |
Why?
|
Th1-Th2 Balance | 1 | 2017 | 10 | 0.150 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2017 | 29 | 0.150 |
Why?
|
Family | 1 | 2019 | 293 | 0.150 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2017 | 45 | 0.150 |
Why?
|
Premature Birth | 1 | 2019 | 150 | 0.150 |
Why?
|
Forecasting | 1 | 2018 | 277 | 0.150 |
Why?
|
Aged | 14 | 2022 | 14842 | 0.150 |
Why?
|
Mentors | 1 | 2017 | 81 | 0.140 |
Why?
|
Adolescent | 9 | 2022 | 8904 | 0.140 |
Why?
|
Medical Informatics Applications | 1 | 2016 | 22 | 0.140 |
Why?
|
Administration, Oral | 3 | 2015 | 411 | 0.140 |
Why?
|
Cells, Cultured | 7 | 2017 | 2673 | 0.140 |
Why?
|
Heart Valve Diseases | 1 | 2017 | 123 | 0.140 |
Why?
|
Cell Adhesion | 1 | 2017 | 324 | 0.140 |
Why?
|
Rheumatology | 1 | 2016 | 46 | 0.140 |
Why?
|
Protein-Arginine Deiminases | 1 | 2015 | 5 | 0.140 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2015 | 3 | 0.140 |
Why?
|
Deoxyribonuclease I | 1 | 2015 | 16 | 0.140 |
Why?
|
Chronic Disease | 2 | 2016 | 1329 | 0.130 |
Why?
|
Protein Array Analysis | 1 | 2015 | 32 | 0.130 |
Why?
|
Hydrolases | 1 | 2015 | 20 | 0.130 |
Why?
|
Isoenzymes | 4 | 2013 | 308 | 0.130 |
Why?
|
Patient Selection | 2 | 2014 | 592 | 0.130 |
Why?
|
Thrombophilia | 1 | 2015 | 21 | 0.130 |
Why?
|
Immunoassay | 1 | 2015 | 64 | 0.130 |
Why?
|
Dinoprost | 2 | 2005 | 27 | 0.130 |
Why?
|
Artificial Intelligence | 1 | 2017 | 159 | 0.130 |
Why?
|
Lung | 3 | 2013 | 849 | 0.130 |
Why?
|
Pulmonary Fibrosis | 2 | 2010 | 157 | 0.130 |
Why?
|
Promoter Regions, Genetic | 4 | 2021 | 614 | 0.130 |
Why?
|
Antimalarials | 1 | 2015 | 71 | 0.130 |
Why?
|
Comorbidity | 1 | 2019 | 1425 | 0.130 |
Why?
|
Adaptation, Psychological | 1 | 2018 | 447 | 0.130 |
Why?
|
Cell Movement | 2 | 2015 | 630 | 0.130 |
Why?
|
Autocrine Communication | 1 | 2015 | 37 | 0.130 |
Why?
|
Cell Membrane Permeability | 1 | 2015 | 59 | 0.130 |
Why?
|
Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 9 | 0.120 |
Why?
|
Behavior Therapy | 1 | 2017 | 297 | 0.120 |
Why?
|
Information Systems | 1 | 2014 | 45 | 0.120 |
Why?
|
Protein Multimerization | 1 | 2015 | 71 | 0.120 |
Why?
|
Neuraminidase | 1 | 2014 | 36 | 0.120 |
Why?
|
Glycosphingolipids | 1 | 2014 | 51 | 0.120 |
Why?
|
Longitudinal Studies | 2 | 2008 | 1054 | 0.120 |
Why?
|
Treatment Outcome | 5 | 2021 | 7028 | 0.120 |
Why?
|
Insulin | 1 | 2017 | 617 | 0.120 |
Why?
|
Anxiety | 1 | 2017 | 422 | 0.120 |
Why?
|
C-Reactive Protein | 1 | 2015 | 180 | 0.120 |
Why?
|
Pregnancy | 2 | 2019 | 2334 | 0.120 |
Why?
|
Quality of Health Care | 1 | 2016 | 322 | 0.120 |
Why?
|
Protein Processing, Post-Translational | 1 | 2015 | 284 | 0.110 |
Why?
|
Health Status | 1 | 2016 | 429 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 766 | 0.110 |
Why?
|
Registries | 1 | 2016 | 730 | 0.110 |
Why?
|
Cell Line | 2 | 2015 | 1752 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2014 | 330 | 0.110 |
Why?
|
Protein Kinase C | 2 | 2004 | 270 | 0.110 |
Why?
|
Logistic Models | 2 | 2017 | 1419 | 0.110 |
Why?
|
Dietary Supplements | 1 | 2015 | 331 | 0.110 |
Why?
|
Albumins | 1 | 2013 | 72 | 0.110 |
Why?
|
Pregnancy Complications | 1 | 2015 | 286 | 0.110 |
Why?
|
Quality Improvement | 1 | 2016 | 413 | 0.110 |
Why?
|
Acetylcysteine | 1 | 2015 | 296 | 0.110 |
Why?
|
Cell Separation | 1 | 2013 | 132 | 0.110 |
Why?
|
Physician's Role | 1 | 2013 | 116 | 0.100 |
Why?
|
Mice, Inbred NZB | 2 | 2005 | 37 | 0.100 |
Why?
|
Antigen-Antibody Complex | 1 | 2013 | 175 | 0.100 |
Why?
|
Mice, Inbred C57BL | 3 | 2022 | 2791 | 0.100 |
Why?
|
Mice, Transgenic | 1 | 2015 | 1033 | 0.100 |
Why?
|
United States | 4 | 2021 | 7338 | 0.100 |
Why?
|
Referral and Consultation | 1 | 2014 | 383 | 0.100 |
Why?
|
Delivery of Health Care | 1 | 2016 | 445 | 0.100 |
Why?
|
Symptom Flare Up | 2 | 2021 | 20 | 0.100 |
Why?
|
Flow Cytometry | 1 | 2013 | 489 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2013 | 226 | 0.100 |
Why?
|
Health Personnel | 1 | 2014 | 286 | 0.100 |
Why?
|
Liver Cirrhosis | 1 | 2015 | 301 | 0.100 |
Why?
|
Stress, Psychological | 1 | 2017 | 824 | 0.090 |
Why?
|
T-Lymphocytes | 1 | 2014 | 597 | 0.090 |
Why?
|
Prostaglandin D2 | 2 | 2001 | 21 | 0.090 |
Why?
|
Gene Expression | 1 | 2013 | 770 | 0.090 |
Why?
|
Aorta | 1 | 2012 | 316 | 0.090 |
Why?
|
Societies, Medical | 1 | 2013 | 403 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2017 | 1046 | 0.090 |
Why?
|
RNA, Messenger | 1 | 2014 | 1663 | 0.090 |
Why?
|
Glomerular Mesangium | 2 | 2001 | 53 | 0.090 |
Why?
|
Depression | 1 | 2017 | 942 | 0.090 |
Why?
|
Amino Acid Transport System y+ | 1 | 2010 | 13 | 0.090 |
Why?
|
Herpesvirus 8, Human | 1 | 2010 | 24 | 0.090 |
Why?
|
Sarcoma, Kaposi | 1 | 2010 | 24 | 0.090 |
Why?
|
Research Design | 1 | 2014 | 729 | 0.090 |
Why?
|
Leukocytes | 1 | 2010 | 99 | 0.090 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 274 | 0.090 |
Why?
|
International Classification of Diseases | 2 | 2022 | 85 | 0.090 |
Why?
|
Lipoproteins, LDL | 1 | 2012 | 343 | 0.090 |
Why?
|
South Carolina | 1 | 2016 | 2752 | 0.090 |
Why?
|
History, 19th Century | 1 | 2009 | 95 | 0.090 |
Why?
|
Societies, Scientific | 1 | 2009 | 18 | 0.080 |
Why?
|
Signal Transduction | 3 | 2015 | 2689 | 0.080 |
Why?
|
Clinical Medicine | 1 | 2009 | 20 | 0.080 |
Why?
|
ROC Curve | 2 | 2021 | 392 | 0.080 |
Why?
|
Calcium | 1 | 2013 | 929 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2010 | 156 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 627 | 0.080 |
Why?
|
Cryoglobulinemia | 1 | 2008 | 5 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2009 | 141 | 0.080 |
Why?
|
Interferon-gamma | 2 | 2007 | 241 | 0.080 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 2008 | 15 | 0.080 |
Why?
|
Hepatitis, Autoimmune | 1 | 2008 | 22 | 0.080 |
Why?
|
Career Choice | 1 | 2009 | 98 | 0.080 |
Why?
|
Immunoglobulin G | 2 | 2022 | 481 | 0.080 |
Why?
|
Risk Factors | 2 | 2012 | 5720 | 0.080 |
Why?
|
Machine Learning | 2 | 2022 | 170 | 0.080 |
Why?
|
Mitochondria | 1 | 2013 | 643 | 0.080 |
Why?
|
Glomerulonephritis | 1 | 2008 | 77 | 0.080 |
Why?
|
Elapid Venoms | 1 | 2007 | 5 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 507 | 0.080 |
Why?
|
Alleles | 2 | 2013 | 386 | 0.080 |
Why?
|
Peroxidase | 1 | 2007 | 40 | 0.080 |
Why?
|
Nitric Oxide Donors | 1 | 2007 | 54 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2021 | 103 | 0.070 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2007 | 8 | 0.070 |
Why?
|
Radioligand Assay | 1 | 2007 | 109 | 0.070 |
Why?
|
Self Efficacy | 2 | 2019 | 199 | 0.070 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2007 | 54 | 0.070 |
Why?
|
Complement Inactivating Agents | 1 | 2007 | 56 | 0.070 |
Why?
|
Medicare | 2 | 2021 | 316 | 0.070 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2007 | 43 | 0.070 |
Why?
|
Qualitative Research | 2 | 2018 | 369 | 0.070 |
Why?
|
Diagnostic Techniques, Urological | 1 | 2005 | 3 | 0.070 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 50 | 0.070 |
Why?
|
Camellia sinensis | 1 | 2005 | 9 | 0.070 |
Why?
|
Tea | 1 | 2005 | 23 | 0.070 |
Why?
|
Lipid Peroxidation | 1 | 2005 | 94 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2007 | 211 | 0.060 |
Why?
|
Diabetic Nephropathies | 1 | 2007 | 161 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2007 | 307 | 0.060 |
Why?
|
Thrombin | 1 | 2004 | 117 | 0.060 |
Why?
|
Curcumin | 1 | 2004 | 23 | 0.060 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2004 | 144 | 0.060 |
Why?
|
Disease Progression | 2 | 2018 | 1037 | 0.050 |
Why?
|
Microsatellite Repeats | 1 | 2003 | 40 | 0.050 |
Why?
|
Linkage Disequilibrium | 1 | 2003 | 91 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2021 | 1738 | 0.050 |
Why?
|
Peptidoglycan | 1 | 2022 | 14 | 0.050 |
Why?
|
Cell Wall | 1 | 2022 | 21 | 0.050 |
Why?
|
Acetyltransferases | 1 | 2022 | 49 | 0.050 |
Why?
|
Spermine | 1 | 2022 | 49 | 0.050 |
Why?
|
Homozygote | 1 | 2022 | 119 | 0.050 |
Why?
|
Sex Distribution | 1 | 2003 | 272 | 0.050 |
Why?
|
Immunoblotting | 2 | 2014 | 254 | 0.050 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2022 | 89 | 0.050 |
Why?
|
Medical Records Systems, Computerized | 1 | 2003 | 130 | 0.050 |
Why?
|
Feces | 1 | 2022 | 88 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2021 | 89 | 0.050 |
Why?
|
Immunoglobulin M | 1 | 2022 | 172 | 0.050 |
Why?
|
Patient Navigation | 1 | 2021 | 30 | 0.050 |
Why?
|
Monocytes | 2 | 2013 | 210 | 0.050 |
Why?
|
Gene Ontology | 1 | 2021 | 31 | 0.050 |
Why?
|
CpG Islands | 1 | 2021 | 51 | 0.050 |
Why?
|
Connective Tissue Diseases | 1 | 2000 | 18 | 0.050 |
Why?
|
Bacteria | 1 | 2022 | 193 | 0.050 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2000 | 72 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2018 | 3256 | 0.040 |
Why?
|
Child | 2 | 2022 | 6401 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2014 | 1174 | 0.040 |
Why?
|
Inflammation Mediators | 1 | 2021 | 244 | 0.040 |
Why?
|
Thiazolidinediones | 1 | 2000 | 76 | 0.040 |
Why?
|
Tight Junctions | 1 | 2019 | 25 | 0.040 |
Why?
|
Inpatients | 1 | 2021 | 208 | 0.040 |
Why?
|
Caco-2 Cells | 1 | 2019 | 37 | 0.040 |
Why?
|
Computational Biology | 1 | 2021 | 190 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 33 | 0.040 |
Why?
|
Permeability | 1 | 2019 | 131 | 0.040 |
Why?
|
Rituximab | 2 | 2010 | 61 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 498 | 0.040 |
Why?
|
Genotype | 2 | 2013 | 785 | 0.040 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 219 | 0.040 |
Why?
|
Unified Medical Language System | 1 | 2017 | 6 | 0.040 |
Why?
|
Mitral Valve Stenosis | 1 | 2017 | 15 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2017 | 52 | 0.040 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2017 | 25 | 0.040 |
Why?
|
Bleomycin | 2 | 2010 | 67 | 0.040 |
Why?
|
DNA, Single-Stranded | 1 | 1997 | 41 | 0.040 |
Why?
|
Aortic Valve Insufficiency | 1 | 2017 | 47 | 0.040 |
Why?
|
Women | 1 | 2017 | 40 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 503 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2017 | 38 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 1753 | 0.040 |
Why?
|
Disease Management | 1 | 2018 | 248 | 0.040 |
Why?
|
Mitral Valve Insufficiency | 1 | 2017 | 99 | 0.040 |
Why?
|
Natural Language Processing | 1 | 2017 | 69 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2016 | 58 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 626 | 0.030 |
Why?
|
Focus Groups | 1 | 2017 | 247 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2017 | 392 | 0.030 |
Why?
|
Heart Valve Prosthesis | 1 | 2017 | 222 | 0.030 |
Why?
|
Creatinine | 2 | 2007 | 243 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1265 | 0.030 |
Why?
|
Biological Products | 1 | 2016 | 78 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2017 | 307 | 0.030 |
Why?
|
Aortic Valve Stenosis | 1 | 2017 | 177 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 155 | 0.030 |
Why?
|
Transfection | 2 | 2010 | 782 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 929 | 0.030 |
Why?
|
Odds Ratio | 1 | 2017 | 880 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2014 | 65 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2014 | 52 | 0.030 |
Why?
|
Urinalysis | 1 | 2014 | 27 | 0.030 |
Why?
|
Aging | 1 | 2020 | 911 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2014 | 114 | 0.030 |
Why?
|
Protein Kinase C-epsilon | 2 | 2004 | 28 | 0.030 |
Why?
|
Heterozygote | 1 | 2014 | 174 | 0.030 |
Why?
|
Medicaid | 1 | 2016 | 301 | 0.030 |
Why?
|
Echocardiography | 1 | 2017 | 515 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2014 | 191 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 209 | 0.030 |
Why?
|
Matrix Attachment Regions | 1 | 2013 | 4 | 0.030 |
Why?
|
Smad3 Protein | 1 | 2013 | 33 | 0.030 |
Why?
|
Smad2 Protein | 1 | 2013 | 42 | 0.030 |
Why?
|
NADH Dehydrogenase | 1 | 2013 | 13 | 0.030 |
Why?
|
Glutathione Reductase | 1 | 2013 | 17 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 48 | 0.030 |
Why?
|
Diet | 1 | 1997 | 514 | 0.030 |
Why?
|
Electron Transport Complex I | 1 | 2013 | 20 | 0.030 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2013 | 35 | 0.030 |
Why?
|
Genetic Loci | 1 | 2013 | 59 | 0.030 |
Why?
|
Haplotypes | 1 | 2013 | 174 | 0.030 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 322 | 0.030 |
Why?
|
Actins | 1 | 2013 | 249 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2014 | 1040 | 0.030 |
Why?
|
Neutrophil Infiltration | 1 | 2010 | 35 | 0.020 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 2 | 2000 | 73 | 0.020 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2010 | 19 | 0.020 |
Why?
|
Phosphorylation | 2 | 2004 | 1200 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 282 | 0.020 |
Why?
|
Cyclooxygenase 2 | 2 | 2000 | 160 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2013 | 1034 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2009 | 109 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 2798 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2009 | 93 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 492 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2005 | 381 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2004 | 617 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2010 | 329 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2010 | 483 | 0.020 |
Why?
|
Radioimmunoprecipitation Assay | 1 | 2007 | 5 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2010 | 799 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2008 | 121 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2007 | 219 | 0.020 |
Why?
|
Debrisoquin | 1 | 1986 | 3 | 0.020 |
Why?
|
Random Allocation | 1 | 2007 | 442 | 0.020 |
Why?
|
Anilides | 1 | 1986 | 16 | 0.020 |
Why?
|
Isoquinolines | 1 | 1986 | 37 | 0.020 |
Why?
|
Internet | 1 | 2009 | 390 | 0.020 |
Why?
|
Macrophages | 1 | 2010 | 647 | 0.020 |
Why?
|
Capsules | 1 | 2005 | 18 | 0.020 |
Why?
|
Catechin | 1 | 2005 | 26 | 0.020 |
Why?
|
Flavonoids | 1 | 2005 | 109 | 0.020 |
Why?
|
Protein Kinase C-alpha | 1 | 2004 | 24 | 0.020 |
Why?
|
Receptor, PAR-1 | 1 | 2004 | 30 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2004 | 37 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2004 | 64 | 0.020 |
Why?
|
Plant Extracts | 1 | 2005 | 122 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 97 | 0.010 |
Why?
|
Heme Oxygenase (Decyclizing) | 1 | 2004 | 11 | 0.010 |
Why?
|
Stress Fibers | 1 | 2004 | 10 | 0.010 |
Why?
|
Cell Size | 1 | 2004 | 76 | 0.010 |
Why?
|
Heme Oxygenase-1 | 1 | 2004 | 40 | 0.010 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 175 | 0.010 |
Why?
|
Drug Resistance | 1 | 2004 | 223 | 0.010 |
Why?
|
Ethics, Research | 1 | 2003 | 12 | 0.010 |
Why?
|
Glutathione Transferase | 1 | 2004 | 166 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2004 | 305 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2004 | 230 | 0.010 |
Why?
|
Hospital Information Systems | 1 | 2003 | 44 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 447 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
Cell Survival | 1 | 2004 | 901 | 0.010 |
Why?
|
Cohort Studies | 1 | 2007 | 2356 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2007 | 2077 | 0.010 |
Why?
|
Antibodies, Anticardiolipin | 1 | 2000 | 15 | 0.010 |
Why?
|
Celecoxib | 1 | 2000 | 22 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 250 | 0.010 |
Why?
|
Peroxisomes | 1 | 2000 | 48 | 0.010 |
Why?
|
Thiazoles | 1 | 2000 | 95 | 0.010 |
Why?
|
Blood Sedimentation | 1 | 1999 | 16 | 0.010 |
Why?
|
Complement C4 | 1 | 1999 | 15 | 0.010 |
Why?
|
NF-kappa B | 1 | 2001 | 432 | 0.010 |
Why?
|
Complement C3 | 1 | 1999 | 101 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 1999 | 4843 | 0.010 |
Why?
|
Encainide | 1 | 1986 | 1 | 0.000 |
Why?
|
Half-Life | 1 | 1986 | 96 | 0.000 |
Why?
|
Kinetics | 1 | 1986 | 1047 | 0.000 |
Why?
|
Electrocardiography | 1 | 1986 | 601 | 0.000 |
Why?
|
Phenotype | 1 | 1986 | 946 | 0.000 |
Why?
|